end-of-study visit not completed within the protocol timeframe

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality.

Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.

This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.

Inclusion Criteria:

• Probant subjects
• Minor or adult subject
• Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
• Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
• Patient affiliated to a valid social security plan

Relative subjects

• Adult subjects
• Subject agreeing to sign the study consent and the biocollection consent
• Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
• Patient affiliated to a social security plan

Exclusion Criteria:

• Subject refusing to participate
• Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
• Subjects under guardianship, curatorship or safeguard of justice or not socially insured
• Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)